ASX/MEDIA RELEASE

ASDM'S LIFE CHANGING ALLVASCULAR PERIPHERAL ACCESS DEVICE (PAD) ACHIEVES TGA APPROVAL

TGA approval permits use for vascular access to trial ground breaking chemotherapy treatment

Sydney, 10th August 2009 - Leading Sydney medical device design and marketing company, Advanced Surgical Design and Manufacture (ASDM) (ASX: AMT), has been granted a Class IIa approval by the Therapeutic Goods Administration (TGA) for its medical breakthrough product, the AllVascular Peripheral Access Device (PAD). This approval means the device, which provides surgeons with vascular access, can be used to trial isolated organ and isolated limb chemotherapy. The TGA approval also permits ASDM to make the PAD available to hospitals in Australia, Europe, Asia and South America with the potential to save thousands of lives through innovative cancer therapy.

The milestone announcement will see the device which has been developed by ASDM used to trial a ground breaking enhancement of the cancer treatment called 'isolated organ perfusion' that has been in use since the 1950s. The PAD allows for multiple uses of balloon catheters or tubes that are inserted into the arteries for treatment. The current method of putting a catheter into an artery requires extensive surgical intervention and is usually only able to be done once or twice for each patient. The new development will allow isolated chemotherapy to be applied as often as required to a specific area, such as the liver or a limb. Isolated organ chemotherapy can be used instead of the traditional method of cancer therapy where chemotherapy drugs are spread throughout the entire body. With isolated organ perfusion, the chemotherapeutic drugs are confined to the part of the body affected by cancer. The PAD will allow a trial of multiple treatments for each patient using isolated organ perfusion with the potential for improved cure rates.

Commenting on the TGA approval, Dr Greg Roger, CEO, ASDM said: "This approval is the next major step for ASDM's PAD development. With the potential to save thousands of lives through cancer therapy, we are delighted the PAD has received Class IIa approval. Isolated organ and limb chemotherapy allows the cancer to be subjected to a higher dose of chemotherapy while at the same time reducing the effect of treatment on the rest of the body. It also may allow the use of treatment agents that are not otherwise able to be used due to their toxicity".

"With huge projected cost savings for the healthcare system, the saving of lives through treatment and the potential upside for ASDM's income, we are excited about the possibilities for this device. Our long term aim is to see specialist centres in major cities across the world using these ASDM-developed technologies," concluded Dr Roger.

Media Contact:

ASDM
Dr Greg Roger
Chief Executive Officer
greg.roger@asdm.com.au
Tel: (02) 9439 4448

Taurus Marketing
Sharon Ghatora or Nick Malham
sharong@taurusmarketing.com.au
nick@taurusmarketing.com.au
Tel: (02) 9415 4528

About ASDM

ASDM designs and manufactures medical devices. Its principal product is the Active Knee, a prosthetic implant of which more than 5,000 have been implanted. This product is supported by a range of Orthopaedic accessories and surgical tools and other Orthopaedic products.

Since 1994 ASDM has provided a highly effective integrated service to surgeons building on its strengths in design and engineering. Core capabilities that underpin this service are integrated design and engineering, regulatory/compliance competency, manufacturing, distribution and customer service.

The company has built an extensive patent and product development portfolio through collaborative research relationships with universities, companies and surgeon inventors that extends beyond orthopaedics. These collaborations are yielding promising projects in several specialities with strong prospects for commercialisation over the next few years.

For more information, please visit www.asdm.com.au